Global Peptide Therapeutics Market 2016-2020

ペプチド治療薬の世界市場:ソマトスタチン、バソプレシン、カルシトニン、LHRH、グルカゴン、インシュリン

◆タイトル:Global Peptide Therapeutics Market 2016-2020
◆商品コード:IRTNTR8630
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年3月4日
◆ページ数:81
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、ペプチド治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、ペプチド治療薬の世界市場規模及び予測、投与経路(ROA)別分析、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・ペプチド治療薬の世界市場:市場規模及び予測
・ペプチド治療薬の世界市場:投与経路(ROA)別分析
・ペプチド治療薬の世界市場:薬剤種類別分析
・ペプチド治療薬の世界市場:地域別分析
・ペプチド治療薬の世界市場:アジア市場規模
・ペプチド治療薬の世界市場:アメリカ市場規模
・ペプチド治療薬の世界市場:ヨーロッパ市場規模
・ペプチド治療薬の世界市場:成長要因
・ペプチド治療薬の世界市場:課題
・市場動向
・競争状況
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Peptide Therapeutics

Peptides are organic compounds that are composed of amino acids linked chemically by peptide bonds. They are the most potent biologically active substances found in nature and are used to trigger, control, and maintain an individual’s physiological processes. However, using peptides as therapeutic agents was always difficult as they are quite instable and cannot pass through cellular membranes. They also require a specific technology to tackle extensive and challenging steps in their synthesis. Over 80 peptides are marketed by companies that explore the probabilities of designing and engineering peptides that can overcome their natural limits. They can be introduced as a treatment for chronic indications.

Technavio’s analysts forecast the global peptide therapeutics market to grow at a CAGR of 7.92% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global peptide therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of prescription and generic drugs used to treat diseases.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Peptide Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Eli Lilly
• Novo Nordisk
• Sanofi
• Takeda Pharmaceutical
• Teva Pharmaceuticals

[Other prominent vendors]
• AbbVie
• Advanced Accelerator Applications
• Akashi Therapeutics
• Amgen
• Anthera Pharmaceuticals
• AstraZeneca
• Bachem
• Bristol-Myers Squibb
• Cardiorentis
• Corden Pharma International
• Debiopharm
• Derma Sciences
• GlaxoSmithKline
• Hanmi Pharmaceutical
• Insmed
• Ipsen
• Johnson & Johnson
• Lonza
• Mallinckrodt
• MolMed
• Merck
• Novartis
• Nymox Pharmaceutical
• Par Pharmaceuticals
• PeptiDream
• Polypeptide Group
• Radius Health
• Repligen
• Roche
• SciClone
• Shire
• The Medicines Company
• Transition Therapeutics
• X-Gen Pharmaceuticals
• Zealand Pharma
• Zydus Cadila

[Market driver]
• Increase in patient population
• For a full, detailed list, view our report

[Market challenge]
• High cost of therapy
• For a full, detailed list, view our report

[Market trend]
• Shifting focus toward untapped markets
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview of peptides
• Peptide synthesis
• Optimization of peptides
• Stabilization of peptides

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation based on route of administration
• Parenteral
• Oral
• Pulmonary
• Mucosal

PART 08: Market segmentation by drug class
• Somatostatins
• Vasopressin
• Calcitonins
• Luteinizing hormone (LH)-releasing hormone (LHRH)
• Glucagon and analogs
• Insulins
• Other

PART 09: Market segmentation by synthesis technology
• Liquid-phase peptide synthesis
• Solid-phase peptide synthesis
• Hybrid peptide synthesis

PART 10: Geographical segmentation
• Global peptide therapeutics market segmentation by geography 2015-2020
• Peptide therapeutics market in Americas
• Peptide therapeutics market in EMEA
• Peptide therapeutics market in APAC

PART 11: Market drivers
• Increase in patient population
• Advances in peptide synthesis technology
• Promising pipeline
• Unmet medical needs
• Increase in healthcare spending

PART 12: Impact of drivers

PART 13: Market challenges
• High cost of therapy
• Adverse side effects
• Stringent regulatory compliances
• Intense market competition

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Growing popularity
• Shifting focus toward untapped markets
• Contract manufacturing
• Increase in public awareness

PART 16: Vendor landscape
• Competitive scenario
• Eli Lilly
• Novo Nordisk
• Sanofi
• Takeda Pharmaceutical
• Teva Pharmaceuticals
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: SWOT analysis: Peptide therapeutics
Exhibit 03: Steps involved in peptide synthesis
Exhibit 04: Optimization of peptide synthesis
Exhibit 05: Methods used to stabilize peptides
Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Global peptide therapeutics market segmentation based on route of administration
Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015
Exhibit 10: Global peptide therapeutics market segmentation by drug class
Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology
Exhibit 12: Global peptide therapeutics market segmentation by geography 2015
Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
Exhibit 25: Eli Lilly: Key takeaways
Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014
Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014
Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014
Exhibit 34: Novo Nordisk: Key takeaways
Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
Exhibit 40: Sanofi: Key takeaways
Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
Exhibit 45: Takeda Pharmaceutical: Key takeaways
Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
Exhibit 47: Teva Pharmaceuticals: Key takeaways



【掲載企業】

Eli Lilly, Novo Nordisk, Sanofi, Takeda Pharmaceutical, Teva Pharmaceuticals, AbbVie, Advanced Accelerator Applications, Akashi Therapeutics, Amgen, Anthera Pharmaceuticals, AstraZeneca, Bachem, Bristol-Myers Squibb, Cardiorentis, Corden Pharma International, Debiopharm, Derma Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Insmed, Ipsen, Johnson & Johnson, Lonza, Mallinckrodt, MolMed, Merck, Novartis, Nymox Pharmaceutical, Par Pharmaceuticals, PeptiDream, Polypeptide Group, Radius Health, Repligen, Roche, SciClone, Shire, The Medicines Company, Transition Therapeutics, X-Gen Pharmaceuticals, Zealand Pharma, Zydus Cadila.

【資料のキーワード】

ペプチド治療薬、ソマトスタチン、バソプレシン、カルシトニン、LHRH、グルカゴン、インシュリン、ペプチド合成、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[ペプチド治療薬の世界市場:ソマトスタチン、バソプレシン、カルシトニン、LHRH、グルカゴン、インシュリン]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆